Brian Culley , CEO / Lineage Cell Therapeutics Info

Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management… [show more]

Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. [hide]

Brandi Roberts , CFO / Lineage Cell Therapeutics Info

Developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and… [show more]

Developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. [hide]

Joseph Pantginis, Ph.D. , Director of Research, Managing Director / H.C. Wainwright & Co., LLC Info

Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he… [show more]

Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine. [hide]